The potential role of intrinsic hypoxia markers as prognostic variables in cancer

Antioxidants and Redox Signaling

Volumn 9, Issue 8, 2007, Pages 1237-1294

  Eui, Jung Moon ^a   Brizel, David M ^a   Chi, Jen Tsan Ashley ^a   Dewhirst, Mark W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; EPIDERMAL GROWTH FACTOR; GLUCOSE TRANSPORTER 1; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 60; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; RAS PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR MARKER; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; COLORECTAL CANCER; ELECTRODE; ENDOMETRIUM CARCINOMA; FIBROSARCOMA; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; HYPOXIA; LUNG CANCER; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER; REVIEW; STANDARDIZATION; STOMACH CANCER; SYSTEMATIC REVIEW;

ANIMALS; ANOXIA; APOPTOSIS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34447503754     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1623     Document Type: Review

References (335)

1. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, and Reynolds JV. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 239: 491-500, 2004.
2. Acs G, Xu X, Chu C, Acs P, and Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 100: 2376-2386, 2004.
3. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, and Semenza GL. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916, 2001.
4. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I, and West C. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7: 928-934, 2001.
5. Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, West CM, and Stratford IJ. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 104: 85-91, 2003.
6. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF, and Livingston DM. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 93: 12969-12973, 1996.
7. Arora S, Kaur J, Sharma C, Mathur M, Bahadur S, Shukla NK, Deo SV, and Ralhan R. Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis. Clin Cancer Res 11: 2272-2284, 2005.
8. Arts HJ, Hollema H, Lemstra W, Willemse PH, De Vries EG, Kampinga HH, and Van der Zee AG. Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int J Cancer 84: 234-238, 1999.
9. Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, and Signoretti S. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11: 3714-3721, 2005.
10. Bachtiary B, Schindl M, Potter R, Dreier B, Knocke TH, Hain fellner JA, Horvat R, and Birner P. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9: 2234-2240, 2003.
11. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, and Noel A. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152: 777-784, 2001.
12. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, and Harper SJ. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62: 4123-4131, 2002.
13. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S, and Harris AL. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62: 2493-2497, 2002.
14. Behrooz A and Ismail-Beigi F. Stimulation of Glucose Transport by Hypoxia: Signals and Mechanisms. News Physiol Sci 14: 105-110, 1999.
15. Benjamin IJ, Kroger B, and Williams RS. Activation of the heat shock transcription factor by hypoxia in mammalian cells. Proc Natl Acad Sci USA 87: 6263-6267, 1990.
16. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22: 4082-4090, 2003.
17. Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, and Allgayer H. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer 106: 1026-1035, 2006.
18. Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rossler K, Prodinger A, Budka H, and Hainfellner JA. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92: 165-171, 2001.
19. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, and Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60: 4693-4696, 2000.
20. Bland KI, Konstadoulakis MM, Vezeridis MP, and Wanebo HJ. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221: 706-718; discussion 718-720, 1995.
21. Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, and Small EJ. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 61: 2533-2536, 2001.
22. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, and van der Wall E. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97: 1573-1581, 2003.
23. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, and Chambers AF. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12: 3337-3343, 2006.
24. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 97: 9082-9087, 2000.
25. Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, and Sahin AA. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res 11: 8398-8402, 2005.
26. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, and Belldegrun AS. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9: 802-811, 2003.
27. Burri P, Djonov V, Aebersold DM, Lindel K, Studer U, Altermatt HJ, Mazzucchelli L, Greiner RH, and Gruber G. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56: 494-501, 2003.
28. Bussink J, Kaanders JH, and van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 67: 3-15, 2003.
29. Calderwood SK, Khaleque MA, Sawyer DB, and Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31: 164-172, 2006.
30. Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, Penalver M, Mancuso S, and Scambia G. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 92: 1144-1150, 2001.
31. Cao Y, Li CY, Moeller BJ, Yu D, Zhao Y, Dreher MR, Shan S, and Dewhirst MW. Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res 65: 5498-5505, 2005.
32. Carroll VA and Ashcroft M. Role of hypoxia-inducible factor (HIF)-1 {alpha} versus HIF-2 {alpha} in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66: 6264-6270, 2006.
33. Chambers SK, Ivins CM, and Carcangiu ML. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 79: 449-454, 1998.
34. Chen CA, Cheng WF, Lee CN, Chen TM, Kung CC, Hsieh FJ, and Hsieh CY. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol 74: 235-240, 1999.
35. Cheng SH, Jian JJ, Tsai SY, Chan KY, Yen LK, Chu NM, Tan TD, Tsou MH, and Huang AT. Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 41: 755-762, 1998.
36. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, Vijver MJ, and Brown PO. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3: e47, 2006.
37. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, and Harris AL. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19: 3660-3668, 2001.
38. Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, and Burtness BA. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 106: 1677-1684, 2006.
39. Ciocca DR and Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10: 86-103, 2005.
40. Ciocca DR, Green S, Elledge RM, Clark GM, Pugh R, Ravdin P, Lew D, Martino S, and Osborne CK. Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study). Clin Cancer Res 4: 1263-1266, 1998.
41. Contente S, Kenyon K, Rimoldi D, and Friedman RM. Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science 249: 796-798, 1990.
42. Cooper R, Sarioglu S, Sokmen S, Fuzun M, Kupelioglu A, Valentine H, Gorken IB, Airley R, and West C. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 89: 870-876, 2003.
43. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, and Foster CS. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60: 7099-7105, 2000.
44. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P, and Charpin C. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 116: 734-739, 2005.
45. Damert A, Ikeda E, and Risau W. Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem J 327 (Pt 2): 419-423, 1997.
46. De Paola F, Granato AM, Scarpi E, Monti F, Medri L, Bianchi S, Amadori D, and Volpi A. Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. Int J Cancer 98: 228-233, 2002.
47. De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, and Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 5: 42, 2005.
48. de Silva Rudland S, Martin L, Roshanlall C, Winstanley J, Leinster S, Platt-Higgins A, Carroll J, West C, Barraclough R, and Rudland P. Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin Cancer Res 12: 1192-1200, 2006.
49. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, and Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991, 1992.
50. de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, van Tienoven TH, Heuvel JJ, Bolt-De Vries J, Benraad TJ, and Foekens JA. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer 80: 286-294, 1999.
51. de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, van Tienoven TH, Heuvel JJ, van Putten WL, Benraad TJ, and Foekens JA. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer 79: 1190-1198, 1999.
52. Demirag F, Unsal E, Yilmaz A, and Caglar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 128: 3382-3387, 2005.
53. Denko NC, Fontana LA, Hudson KM, Sutphin PD, Raychaudhuri S, Altman R, and Giaccia AJ. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22: 5907-5914, 2003.
54. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, and Berthois Y. Clinical relevance of amphiregulin and VEGF in primary breast cancers. Int J Cancer 111: 733-740, 2004.
55. DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, and Karin M. Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 16: 1295-1304, 1996.
56. Dimova EY, Samoylenko A, and Kietzmann T. Oxidative stress and hypoxia: implications for plasminogen activator inhibitor-1 expression. Antioxid Redox Signal 6: 777-791, 2004.
57. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J. Sauleda S, Alcover J, Campo E, Gascon P, Rovira A, Ross JS, Fernandez PL, and Albanell J. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 93: 1285-1294, 2005.
58. Donati V, Boldrini L, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, and Fontanini G. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11: 6459-6465, 2005.
59. Dressman HK, Hans C, Bild A, Olson JA, Rosen E, Marcom PK, Liotcheva VB, Jones EL, Vujaskovic Z, Marks J, Dewhirst MW, West M, Nevins JR, and Blackwell K. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 12: 819-826, 2006.
60. Druzgal CH, Chen Z, Yeh NT, Thomas GR, Ondrey FG, Duffey DC, Vilela RJ, Ende K, McCullagh L, Rudy SF, Muir C, Herscher LL, Morris JC, Albert PS, and Van Waes C. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head Neck 27: 771-784, 2005.
61. Dudek AZ and Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 23: 193-200, 2005.
62. Ebert BL, Firth JD, and Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem 270: 29083-29089, 1995.
63. Edwards J, Krishna NS, Mukherjee R, and Bartlett JM. The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. J Pathol 204: 153-158, 2004.
64. Eferl R and Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868, 2003.
65. Elpek GO, Karaveli S, Simsek T, Keles N, and Aksoy NH. Expression of heat-shock proteins hsp27, hsp70 and hsp90 in malignant epithelial tumour of the ovaries. Apmis 111: 523-530, 2003.
66. Enatsu S, Iwasaki A, Shirakusa T, Hamasaki M, Nabeshima K, Iwasaki H, Kuroki M, and Kuroki M. Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in smallsized adenocarcinomas of the lung. Eur J Cardiothorac Surg 29: 891-895, 2006.
67. Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Buchler MW, Giese NA, and Friess H. Loss of BNJP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 24: 4421-4432, 2005.
68. Erkizan O, Kirkali G, Yorukoglu K, and Kirkali Z. Significance of heat shock protein-27 expression in patients with renal cell carcinoma. Urology 64: 474-478, 2004.
69. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, and Giaccia AJ. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440: 1222-1226, 2006.
70. Evans SM and Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 195: 1-16, 2003.
71. Faderl S, Do KA, Johnson MM, Keating M, O'Brien S, Jilani I, Ferrajoli A, Ravandi-Kashani F, Aguilar C, Dey A, Thomas DA, Giles FJ, Kantarjian HM, and Albitar M. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 106: 4303-4307, 2005.
72. Faried A, Sohda M, Nakajima M, Miyazaki T, Kato H, and Kuwano H. Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma. Eur J Cancer 40: 2804-2811, 2004.
73. Farrell F and Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9 Suppl 5: 18-30, 2004.
74. Fernandez PM, Tabbara SO, Jacobs LK, Manning FC, Tsangaris TN, Schwartz AM, Kennedy KA, and Patierno SR. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat 59: 15-26, 2000.
75. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
76. Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U, and Buerger H. HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5: 84, 2005.
77. Fink T, Kazlauskas A, Poellinger L, Ebbesen P, and Zachar V. Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood 99: 2077-2083, 2002.
78. Firth JD, Ebert BL, Pugh CW, and Ratcliffe PJ. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 91: 6496-6500, 1994.
79. Firth JD, Ebert BL, and Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 270: 21021-21027, 1995.
80. Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Janicke F, and Klijn JG. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658, 1994.
81. Fondevila C, Metges JP, Fuster J, Grau JJ, Palacin A, Castells A, Volant A, and Pera M. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90: 206-215, 2004.
82. Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K, and Ke Y. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 118: 2255-2261, 2006.
83. Fukata S, Inoue K, Kamada M, Kawada C, Furihata M. Ohtsuki Y, and Shuin T. Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer 103: 931-942, 2005.
84. Galizia G, Lieto E, Ferraraccio F, Orditura M, De Vita F, Castellano P, Imperatore V, Romano C, Ciardiello F, Agostini B, and Pignatelli C. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 10: 3490-3499, 2004.
85. Galland F, Karamysheva A, Pebusque MJ, Borg JP, Rottapel R, Dubreuil P, Rosnet O, and Birnbaum D. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene 8: 1233-1240, 1993.
86. Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP, and Solary E. HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J 13: 2061-2070, 1999.
87. Gee JM, Barroso AF, Ellis IO, Robertson JF, and Nicholson RI. Biological and clinical associations of c-jun activation in human breast cancer. Int J Cancer 89: 177-186, 2000.
88. Geisler JP, Geisler HE, Tammela J, Miller GA, Wiemann MC, and Zhou Z. A study of heat shock protein 27 in endometrial carcinoma. Gynecol Oncol 72: 347-350, 1999.
89. Geisler JP, Geisler HE, Tammela J, Wiemann MC, Zhou Z, Miller GA, and Crabtree W. Heat shock protein 27: an independent prognostic indicator of survival in patients with epithelial ovarian carcinoma. Gynecol Oncol 69: 14-16, 1998.
90. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, and Kantoff PW. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7: 1932-1936, 2001.
91. Giampuzzi M, Botti G, Cilli M, Gusmano R, Borel A, Sommer P, and Di Donato A. Down-regulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of ras proto-oncogene. J Biol Chem 276: 29226-29232, 2001.
92. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, and Harris AL. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61: 7992-7998, 2001.
93. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC, and Harris AL. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85: 881-890, 2001.
94. Giatromanolaki A, Koukourakis MI, Sowter HM, Sivridis E, Gibson S, Gatter KC, and Harris AL. BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. Clin Cancer Res 10: 5566-5571, 2004.
95. Gilbert SM, Whitson JM, Mansukhani M, Buttyan R, Benson MC, Olsson CA, Sawczuk IS, and McKiernan JM. Detection of carbonic anhydrase-9 gene expression in peripheral blood cells pre-diets risk of disease recurrence in patients with renal cortical tumors. Urology 67: 942-945, 2006.
96. Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR, and Buller RE. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res 11: 3733-3742, 2005.
97. Grondahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Dano K, and Brunner N. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin Cancer Res 3: 233-239, 1997.
98. Grover-McKay M, Walsh SA, Seftor EA, Thomas PA, and Hendrix MJ. Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res 4: 115-120, 1998.
99. Gruber G, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G, and Djonov V. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res 6: R191-198, 2004.
100. Gu YZ, Moran SM, Hogenesch JB, Wartman L, and Bradfield CA. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 7: 205-213, 1998.
101. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, and Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 60: 5839-5847, 2000.
102. Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastorekova S, Pastorek J, Parkkila SM, and Haapasalo HK. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12: 473-477, 2006.
103. Hanahan D and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
104. Hansen S, Overgaard J, Rose C, Knoop A, Laenkholm AV, Andersen J, Sorensen FB, and Andreasen PA. Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. Br J Cancer 88: 102-108, 2003.
105. Hara S, Hamada J, Kobayashi C, Kondo Y, and Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. Biochem Biophys Res Commun 287: 808-813, 2001.
106. Harbeck N, Alt U, Berger U, Kruger A, Thomssen C, Janicke F, Hofler H, Kates RE, and Schmitt M. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 7: 2757-2764, 2001.
107. Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE. Hofler H, Janicke F, Graeff H, and Schmitt M. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 54: 147-157, 1999.
108. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, and Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 12: 332-339, 2006.
109. Hazelbag S, Kenter GG, Gorter A, and Fleuren GJ. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. Int J Cancer 112: 1020-1028, 2004.
110. Hedley D, Pintilie M, Woo J, Morrison A, Birle D, Fyles A, Milosevic M, and Hill R. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res 9: 5666-5674, 2003.
111. Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempfer CB, and Reinthaller A. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 103: 512-517, 2006.
112. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, and Schildberg FW. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 13: 2084-2093, 1995.
113. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-4515, 1996.
114. Hockel M, Schlenger K, Knoop C, and Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res 51: 6098-6102, 1991.
115. Hoskin PJ, Sibtain A, Daley FM, and Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 89: 1290-1297, 2003.
116. Hotte SJ, Winquist EW, Stitt L, Wilson SM, and Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95: 506-512, 2002.
117. Hsu WM, Hsieh FJ, Jeng YM, Kuo ML, Tsao PN, Lee H, Lin MT, Lai HS, Chen CN, Lai DM, and Chen WJ. GRP78 expression correlates with histologic differentiation and favorable prognosis in neuroblastic tumors. Int J Cancer 113: 920-927, 2005.
118. Huang C, Liu D, Masuya D, Nakashima T, Kameyama K, Ishikawa S, Ueno M, Haba R, and Yokomise H. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 92: 1231-1239, 2005.
119. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, and Harris AL. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8: 2595-2604, 2002.
120. Hussain SA, Palmer DH, Ganesan R, Hiller L, Gregory J, Murray PG, Pastorek J, Young L, and James ND. Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncol Rep 11: 1005-1010, 2004.
121. Hutchison GJ, Valentine HR, Loncaster JA, Davidson SE, Hunter RD, Roberts SA, Harris AL, Stratford IJ, Price PM, and West CM. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 10: 8405-8412, 2004.
122. Ino K, Shibata K, Kajiyama H, Yamamoto E, Nagasaka T, Nawa A, Nomura S, and Kikkawa F. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer 94: 552-560, 2006.
123. Inoshima N, Nakanishi Y, Minami T, Izumi M, Takayama K, Yoshino I, and Hara N. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res 8: 3480-3486, 2002.
124. Ishikawa H, Sakurai H, Hasegawa M, Mitsuhashi N, Takahashi M, Masuda N, Nakajima M, Kitamoto Y, Saitoh J, and Nakano T. Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int J Radiat Oncol Biol Phys 60: 513-521, 2004.
125. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG, Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for 02 sensing. Science 292: 464-468, 2001.
126. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, and Stanbridge EJ. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158: 905-919, 2001.
127. Iwasaki A, Kuwahara M, Yoshinaga Y, and Shirakusa T. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg 25: 443-448, 2004.
128. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, and Ajani JA. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24: 748-754, 2006.
129. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, and Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 93: 297-302, 2004.
130. Jamora C, Dennert G, and Lee AS. Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Proc Natl Acad Sci USA 93: 7690-7694, 1996.
131. Jeay S, Pianetti S, Kagan HM, and Sonenshein GE. Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. Mol Cell Biol 23: 2251-2263, 2003.
132. Jelkmann W. Molecular biology of erythropoietin. Intern Med 43: 649-659, 2004.
133. Jenkins WT, Evans SM, and Koch CJ. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode. Int J Radiat Oncol Biol Phys 46: 1005-1017, 2000.
134. Jonathan RA, Wijffels KI, Peeters W, de Wilde PC, Marres HA, Merkx MA, Oosterwijk E, van der Kogel AJ, and Kaanders JH. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 79: 288-297, 2006.
135. Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, and Hocker M. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 24: 228-240, 2006.
136. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den
137. Kapranos N, Kominea A, Konstantinopoulos PA, Sawa S, Artelaris S, Vandoros G, Sotiropoulou-Bonikou G, and Papavassiliou AG. Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol 128: 426-432, 2002.
138. Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, and Karatzas G. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 236: 37-42, 2002.
139. Kasimir-Bauer S, Beelen D, Flasshove M, Noppeney R, Seeber S, and Scheulen ME. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia. Exp Hematol 30: 1302-1308, 2002.
140. Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam Eel D, and Khalifa A. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 37: 363-369, 2004.
141. Katsuta M, Miyashita M, Makino H, Nomura T, Shinji S, Yamashita K, Tajiri T, Kudo M, Ishiwata T, and Naito Z. Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp Mol Pathol 78: 123-130, 2005.
142. Kaur J, Srivastava A, and Ralhan R. Expression of 70-kDa heat shock protein in oral lesions: marker of biological stress or pathogenicity. Oral Oncol 34: 496-501, 1998.
143. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, Honma K, and Suzuki T. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 92: 634-641, 2001.
144. Kawanishi K, Shiozaki H, Doki Y, Sakita I, Inoue M, Yano M, Tsujinaka T, Shamma A, and Monden M. Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus. Cancer 85: 1649-1657, 1999.
145. Kaya A, Ciledag A, Gulbay BE, Poyraz BM, Celik G, Sen E, Savas H, and Savas I. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 98: 632-636, 2004.
146. Kido S, Kitadai Y, Hattori N, Haruma K, Kido T, Ohta M, Tanaka S, Yoshihara M, Sumii K, Ohmoto Y, and Chayama K. Interleukin 8 and vascular endothelial growth factor - prognostic factors in human gastric carcinomas? Eur J Cancer 37: 1482-1487, 2001.
147. Kietzmann T, Roth U, and Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 94: 4177-4185, 1999.
148. Kim JY, Shin HJ, Kim TH, Cho KH, Shin KH, Kim BK, Roh JW, Lee S, Park SY, Hwang YJ, and Han IO. Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. J Cancer Res Clin Oncol 132: 302-308, 2006.
149. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, and Ferrara N. Inhibition of vascular endothelial growth factor-in duced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.
150. Kim SH, Cho NH, Kim K, Lee JS, Koo BS, Kim JH, Chang JH, and Choi EC. Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression. J Surg Oncol 93: 330-337, 2006.
151. Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG, Oosterwijk E, and Kelley MJ. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49: 325-335, 2005.
152. Kim SJ, Rabbani ZN, Vollmer RT, Schreiber EG, Oosterwijk E, Dewhirst MW, Vujaskovic Z, and Kelley MJ. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 10: 7925-7933, 2004.
153. Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H, and Takai S. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 4: 177-182, 1998.
154. Kimura E, Enns RE, Alcaraz JE, Arboleda J, Slamon DJ, and Howell SB. Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol 11: 891-898, 1993.
155. Kimura S, Kitadai Y, Tanaka S, Kuwai T, Hihara J, Yoshida K, Toge T, and Chayama K. Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer 40: 1904-1912, 2004.
156. King KL, Li AF, Chau GY, Chi CW, Wu CW, Huang CL, and Lui WY. Prognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer 88: 2464-2470, 2000.
157. Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, Sommer P, Csiszar K, and Hendrix MJ. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 62: 4478-4483, 2002.
158. Kirschmann DA, Seftor EA, Nieva DR, Mariano EA, and Hendrix MJ. Differentially expressed genes associated with the metastatic phenotype in breast cancer. Breast Cancer Res Treat 55: 127-136, 1999.
159. Koga F, Kageyama Y, Kawakami S, Fujii Y, Hyochi N, Ando N, Takizawa T, Saito K, Iwai A, Masuda H, and Kihara K. Prognostic significance of endothelial Per-Arnt-sim domain protein 1/hypoxia-inducible factor-2alpha expression in a subset of tumor associated macrophages in invasive bladder cancer. J Urol 171: 1080-1084, 2004.
160. Kojima H, Shijubo N, Yamada G, Ichimiya S, Abe S, Satoh M, and Sato N. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer 104: 1668-1677, 2005.
161. Kondo K, Klco J, Nakamura E, Lechpammer M, and Kaelin WG, Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246, 2002.
162. Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D, and Pegram M. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 7: 1743-1749, 2001.
163. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, and Pegram MD. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10: 1706-1716, 2004.
164. Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C, Evans S, Ibrahim H, Le QT, Terris DJ, and Giaccia AJ. Candidate genes for the hypoxic tumor phenotype. Cancer Res 60: 883-887, 2000.
165. Kothari S, Cizeau J, McMillan-Ward E, Israels SJ, Bailes M, Ens K, Kirshenbaum LA, and Gibson SB. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 22: 4734-4744, 2003.
166. Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, Dische S, Sivridis E, and Harris AL. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24: 727-735, 2006.
167. Koukourakis MI, Giatromanolaki A, Simopoulos C, Polychronidis A, and Sivridis E. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 22: 25-30, 2005.
168. Koukourakis Ml, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, and Harris AL. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 89: 877-885, 2003.
169. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, Gatter KC, and Harris AL. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53: 1192-1202, 2002.
170. Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC, and Harris AL. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 61: 1830-1832, 2001.
171. Kronblad A, Jirstrom K, Ryden L, Nordenskjold B, and Landberg G. Hypoxia inducible factor-1alpha is a prognostic marker in pre-menopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer 118: 2609-2616, 2006.
172. Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Spathe K, Dettmar P, Hofler H, Janicke F, Schmitt M, and Graeff H. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 79: 1746-1751, 1999.
173. Kung AL, Wang S, Klco JM, Kaelin WG, and Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6: 1335-1340, 2000.
174. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, Bartenstein P, Wagner W, and Whiteside TL. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97: 1015-1024, 2003.
175. Kurahara H, Takao S, Maemura K, Shinchi H, Natsugoe S, and Aikou T. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin Cancer Res 10: 8413-8420, 2004.
176. Kurokawa T, Miyamoto M, Kato K, Cho Y, Kawarada Y, Hida Y, Shinohara T, Itoh T, Okushiba S, Kondo S, and Katoh H. Overexpression of hypoxia-inducible- factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer 89: 1042-1047, 2003.
177. Kute TE, Grondahl-Hansen J, Shao SM, Long R, Russell G, and Brunner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 47: 9-16, 1998.
178. Kyzas PA, Cunha IW, and Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 11: 1434-1440, 2005.
179. Kyzas PA, Stefanou D, Batistatou A, and Agnantis NJ. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 131: 624-630, 2005.
180. Laack E, Scheffler A, Burkholder I, Boeters I, Andritzky B, Schuch G, Gorn M, Vohwinkel G, Edler L, Fiedler W, and Hossfeld DK. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 50: 51-58, 2005.
181. Laderoute KR, Calaoagan JM, Gustafson-Brown C, Knapp AM, Li GC, Mendonca HL, Ryan HE, Wang Z, and Johnson RS. The response of c-jun/AP-1 to chronic hypoxia is hypoxia-inducible factor 1 alpha dependent. Mol Cell Biol 22: 2515-2523, 2002.
182. Lai A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, Kaanders JH, van der Kogel AJ, and Riggins GJ. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93: 1337-1343, 2001.
183. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC, and Giaccia AJ. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 12: 1507-1514, 2006.
184. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, and Giaccia AJ. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9: 59-67, 2003.
185. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 26: 504-510, 2001.
186. Lee BL, Lee HS, Jung J, Cho SJ, Chung HY, Kim WH, Jin YW, Kim CS, and Nam SY. Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res 11: 2518-2525, 2005.
187. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, and Ljungberg B. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11: 1129-1135, 2005.
188. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, and Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 18: 1423-1431, 2000.
189. Linderholm B, Tavelin B, Grankvist K, and Henriksson R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16: 3121-3128, 1998.
190. Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD, and West CM. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 83: 620-625, 2000.
191. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, and West CM. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61: 6394-6399, 2001.
192. Luo S, Baumeister P, Yang S, Abcouwer SF, and Lee AS. Induction of Grp78/BiP by translational block: activation of the Grp78 promoter by ATF4 through and upstream ATF/CRE site independent of the endoplasmic reticulum stress elements. J Biol Chem 278: 37375-37385, 2003.
193. Macheda ML, Rogers S, and Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202: 654-662, 2005.
194. Mahon PC, Hirota K, and Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675-2686, 2001.
195. Manders P, Sweep FC, Tjan-Heijnen VC, Geurts-Moespot A, van Tienoven DT, Foekens JA, Span PN, Bussink J, and Beex LV. Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients. Clin Cancer Res 9: 6363-6370, 2003.
196. Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, and Sweep FC. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Cancer 101: 486-494, 2004.
197. Mandic A, Hansson J, Linder S, and Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 278: 9100-9106, 2003.
198. Martinez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J, Castrillo JM, Rivas C, and Benitez J. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 19: 2254-2263, 2005.
199. Maseide K, Kandel RA, Bell RS, Catton CN, O'Sullivan B, Wunder JS, Pintilie M, Hedley D, and Hill RP. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res 10: 4464-4471, 2004.
200. Matsuyama T, Nakanishi K, Hayashi T, Yoshizumi Y, Aiko S, Sugiura Y, Tanimoto T, Uenoyama M, Ozeki Y, and Maehara T. Expression of hypoxia-inducible factor-1alpha in esophageal squamous cell carcinoma. Cancer Sci 96: 176-182, 2005.
201. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, and Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999.
202. Mayer A, Hockel M, and Vaupel P. Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix. Clin Cancer Res 11: 7220-7225, 2005.
203. Mayer A, Hockel M, Wree A, and Vaupel P. Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers. Clin Cancer Res 11: 2768-2773, 2005.
204. Mayer A, Wree A, Hockel M, Leo C, Pilch H, and Vaupel P. Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Res 64: 5876-5881, 2004.
205. Menon C and Fraker DL. Tumor oxygenation status as a prognostic marker. Cancer Lett 221: 225-235, 2005.
206. Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S, and Chouchane L. Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 91: 672-678, 2001.
207. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, and Strawn LM. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56: 1615-1620, 1996.
208. Minami K, Saito Y, Imamura H, and Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 38: 51-57, 2002.
209. Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B, and Tonini G. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol 57: 591-597, 2004.
210. Moeller BJ, Cao Y, Li CY, and Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 429-441, 2004.
211. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540, 1999.
212. Muracciole X, Romain S, Dufour H, Palmari J, Chinot O, Ouafik L, Grisoli F, Branger DF, and Martin PM. PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int J Radiat Oncol Biol Phys 52: 592-598, 2002.
213. Murai M, Toyota M, Suzuki H, Satoh A, Sasaki Y, Akino K, Ueno M, Takahashi F, Kusano M, Mita H, Yanagihara K, Endo T, Hinoda Y, Tokino T, and Imai K. Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res 11: 1021-1027, 2005.
214. Murakami Y, Kanda K, Tsuji M, Kanayama H, and Kagawa S. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int 83: 743-747, 1999.
215. Nakajima M, Kuwano H, Miyazaki T, Masuda N, and Kato H. Significant correlation between expression of heat shock proteins 27, 70 and lymphocyte infiltration in esophageal squamous cell carcinoma. Cancer Lett 178: 99-106, 2002.
216. Nakanishi K, Hiroi S, Tominaga S, Aida S, Kasamatsu H, Matsuyama S, Matsuyama T, and Kawai T. Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin Cancer Res 11: 2583-2590, 2005.
217. Newell K, Franchi A, Pouyssegur J, and Tannock I. Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci USA 90: 1127-1131, 1993.
218. Nishida N, Yano H, Komai K, Nishida T, Kamura T, and Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 101: 1364-1374, 2004.
219. Nordsmark M, Loncaster J, Chou SC, Havsteen H, Lindegaard JC, Davidson SE, Varia M, West C, Hunter R, Overgaard J, and Raleigh JA. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys 49: 581-586, 2001.
220. Nordsmark M, Overgaard M, and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: 31-39, 1996.
221. Oesterreich S, Hilsenbeck SG, Ciocca DR, Allred DC, Clark GM, Chamness GC, Osborne CK, and Fuqua SA. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res 2: 1199-1206, 1996.
222. Okami J, Simeone DM, and Logsdon CD. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 64: 5338-5346, 2004.
223. Oliver RJ, Woodwards RT, Sloan P, Thakker NS, Stratford IJ, and Airley RE. Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. Eur J Cancer 40: 503-507, 2004.
224. Onesto C, Hannoun-Levi JM, Chamorey E, Formento JL, Ramaioli A, and Pages G. Vascular endothelial growth factor-A and Poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance. Br J Cancer 94: 1516-1523, 2006.
225. Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S, and Chayama K. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 95: 32-39, 2004.
226. Ottaiano A, Franco R, Aiello Talamanca A, Liguori G, Tatangelo F, Delrio P, Nasti G, Barletta E, Facchini G, Daniele B, Di Blasi A, Napolitano M, Ierano C, Calemma R, Leonardi E, Albino V, De Angelis V, Falanga M, Boccia V, Capuozzo M, Parisi V, Botti G, Castello G, Vincenzo Iaffaioli R, and Scala S. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 12: 2795-2803, 2006.
227. Palit V, Phillips RM, Puri R, Shah T, and Bibby MC. Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncol Rep 14: 909-913, 2005.
228. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, and Hsu HC. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98: 119-127, 2003.
229. Pappot H, Pedersen AN, Brunner N, and Christensen IJ. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis. Lung Cancer 51: 193-200, 2006.
230. Paris S, Denis H, Delaive E, Dieu M, Dumont V, Ninane N, Raes M, and Michiels C. Up-regulation of 94-kDa glucose-regulated protein by hypoxia-inducible factor-1 in human endothelial cells in response to hypoxia. FEBS Lett 579: 105-114, 2005.
231. Payne SL, Fogelgren B, Hess AR, Seftor EA, Wiley EL, Fong SF, Csiszar K, Hendrix MJ, and Kirschmann DA. Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res 65: 11429-11436, 2005.
232. Pedersen AN, Christensen IJ, Stephens RW, Briand P, Mouridsen HT, Dano K, and Brunner N. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res 60: 6927-6934, 2000.
233. Pikarsky E and Ben-Neriah Y. NF-kappaB inhibition: a double-edged sword in cancer? Eur J Cancer 42: 779-784, 2006.
234. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, and Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91: 1354-1360, 2004.
235. Pore N, Liu S, Shu HK, Li B, Haas-Kogan D, Stokoe D, Milanini-Mongiat J, Pages G, O'Rourke DM, Bernhard E, and Maity A. Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 15: 4841-4853, 2004.
236. Preusser M, Wolfsberger S, Haberler C, Breitschopf H, Czech T, Slave I, Harris AL, Acker T, Budka H, and Hainfellner JA. Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathol (Berl) 109: 211-216, 2005.
237. Rangaswami H, Bulbule A, and Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16: 79-87, 2006.
238. Ray R, Chen G, Vande Velde C, Cizeau J, Park JH, Reed JC, Gietz RD, and Greenberg AH. BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J Biol Chem 275: 1439-1448, 2000.
239. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, and Lee AS. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 278: 20915-20924, 2003.
240. Ribas C, Colleoni GW, Silva MR, Carregoza MJ, and Bordin JO. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. Eur J Haematol 73: 311-317, 2004.
241. Ricaniadis N, Kataki A, Agnantis N, Androulakis G, and Karakousis CP. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Eur J Surg Oncol 27: 88-93, 2001.
242. Richard DE, Berra E, Gothie E, Roux D, and Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor lalpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274: 32631-32637, 1999.
243. Rittling SR and Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 90: 1877-1881, 2004.
244. Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP, Jr., Kaur P, Gray K, and Stringer B. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 10: 2466-2472, 2004.
245. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, and West CR. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62: 3417-3427, 2002.
246. Saad RS, El-Gohary Y, Memari E, Liu YL, and Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol 36: 955-961, 2005.
247. Sakakibara T, Hibi K, Kodera Y, Ito K, Akiyama S, and Nakao A. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma. Clin Cancer Res 10: 1375-1378, 2004.
248. Santarosa M, Favaro D, Quaia M, and Galligioni E. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer 33: 873-877, 1997.
249. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, and Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8: 1831-1837, 2002.
250. Schmedtje JF, Jr., Ji YS, Liu WL, DuBois RN, and Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272: 601-608, 1997.
251. Schmitz ML and Baeuerle PA. The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO J 10: 3805-3817, 1991.
252. Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Holscher AH, and Danenberg PV. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 10: 1588-1596, 2004.
253. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 19: 176-182, 2004.
254. Semenza GL and Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454, 1992.
255. Shaulian E and Karin M. AP-1 in cell proliferation and survival. Oncogene 20: 2390-2400, 2001.
256. Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, and Sugisaki Y. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83: 196-203, 2000.
257. Shen J, Hughes C, Chao C, Cai J, Barrels C, Gessner T, and Subjeck J. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc Natl Acad Sci USA 84: 3278-3282, 1987.
258. Shida A, Fujioka S, Ishibashi Y, Kobayashi K, Nimura H, Mitsumori N, Suzuki Y, Kawakami M, Urashima M, and Yanaga K. Prognostic significance of vascular endothelial growth factor D in gastric carcinoma. World J Surg 29: 1600-1607, 2005.
259. Shijubo N, Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M, and Abe S. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160: 1269-1273, 1999.
260. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, and Dang CV. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 94: 6658-6663, 1997.
261. Shimanuki Y, Takahashi K, Cui R, Hori S, Takahashi F, Miyamoto H, and Fukurchi Y. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 183: 29-42, 2005.
262. Shweiki D, Itin A, Soffer D, and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
263. Simi L, Venturini G, Malentacchi F, Gelmini S, Andreani M, Janni A, Pastorekova S, Supuran CT, Pazzagli M, and Orlando C. Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer. Lung Cancer 52: 59-66, 2006.
264. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, and Harris JF. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3: 605-611, 1997.
265. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, and Koukourakis MI. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95: 1055-1063, 2002.
266. Smith BD, Smith GL, Carter D, DiGiovanna MP, Kasowitz KM, Sasaki CT, and Haffty BG. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 127: 780-785, 2001.
267. Soker S, Takashima S, Miao HQ, Neufeld G, and Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745, 1998.
268. Sorensen BS, Hao J, Overgaard J, Vorum H, Honore B, Alsner J, and Horsman MR. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 76: 187-193, 2005.
269. Soumaoro LT, Uetake H, Takagi Y, Iida S, Higuchi T, Yasuno M, Enomoto M, and Sugihara K. Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum 49: 392-398, 2006.
270. Sowter HM, Ferguson M, Pym C, Watson P, Fox SB, Han C, and Harris AL. Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. J Pathol 201: 573-580, 2003.
271. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, and Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 63: 6130-6134, 2003.
272. Span PN, Bussink J, Manders P, Beex LV, and Sweep CG. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 89: 271-276, 2003.
273. Sreedhar AS and Csermely P. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol Ther 101: 227-257, 2004.
274. Stackhouse BL, Williams H, Berry P, Russell G, Thompson P, Winter JL, and Kute T. Measurement of glut-1 expression using tissue microarrays to determine a race specific prognostic marker for breast cancer. Breast Cancer Res Treat 93: 247-253, 2005.
275. Stein B, Baldwin AS, Jr., Ballard DW, Greene WC, Angel P, and Herrlich P. Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. Embo. J 12: 3879-3891, 1993.
276. Subjeck JR and Shyy TT. Stress protein systems of mammalian cells. Am J Physiol 250: C1-17, 1986.
277. Sulzbacher I, Birner P, Trieb K, Lang S, and Chott A. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch 441: 345-349, 2002.
278. Sun XF, Zhang H, Carstensen J, Jansson A, and Nordenskjold B. Heat shock protein 72/73 in relation to cytoplasmic p53 expression and prognosis in colorectal adenocarcinomas. Int J Cancer 74: 600-604, 1997.
279. Svastova E, Hulikova A, Rafajova M, Zat'ovicova M, Gibadulinova A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J, and Pastorekova S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 577: 439-445, 2004.
280. Swinson DE, Cox G, and O'Byrne KJ. Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. Br J Cancer 91: 1301-1307, 2004.
281. Swinson DE, Jones JL, Cox G, Richardson D, Harris AL, and O'Byrne KJ. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer 111: 43-50, 2004.
282. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, and O'Byrne KJ. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21: 473-482, 2003.
283. Syrigos KN, Harrington KJ, Karayiannakis AJ, Sekara E, Chatziyianni E, Syrigou EI, and Waxman J. Clinical significance of heat shock protein-70 expression in bladder cancer. Urology 61: 677-680, 2003.
284. Takenaka K, Katakura H, Chen F, Ogawa E, Adachi M, Wada H, and Tanaka F. The ratio of membrane-bound form Fit-1 mRNA to VEGF mRNA correlates with tumor angiogenesis and prognosis in non-small cell lung cancer. Cancer Lett 246: 34-40, 2007.
285. Takeno S, Noguchi T, Kikuchi R, Sato T, Uchida Y, and Yokoyama S. Analysis of the survival period in resectable stage IV gastric cancer. Ann Surg Oncol 8: 215-221, 2001.
286. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, and Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157: 411-421, 2000.
287. Tas F, Aydiner A, Demir C, and Topuz E. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol 24: 376-378, 2001.
288. Tas F, Aykan F, Alici S, Kaytan E, Aydiner A, and Topuz E. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 24: 547-550, 2001.
289. Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, and Wittliff JL. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. Gynecol Oncol 80: 48-55, 2001.
290. Teknos TN, Cox C, Yoo S, Chepeha DB, Wolf GT, Bradford CR, Carey TE, and Fisher SG. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 24: 1004-1011, 2002.
291. Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, and Kainz C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 92: 360-363, 1998.
292. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, and Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187: 1579-1586, 1992.
293. Thanos D and Maniatis T. NF-kappa B: a lesson in family values. Cell 80: 529-532, 1995.
294. Theodoropoulos VE, Lazaris A, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, Manikas K, and Kastriotis I. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 46: 200-208, 2004.
295. Theodoropoulos VE, Lazaris AC, Kastriotis I, Spiliadi C, Theodoropoulos GE, Tsoukala V, Patsouris E, and Sofras F. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 95: 425-431, 2005.
296. Thomas X, Campos L, Mounier C, Cornillon J, Flandrin P, Le QH, Piselli S, and Guyotat D. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 29: 1049-1058, 2005.
297. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, and Abraham JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947-11954, 1991.
298. Tsan MF and Gao B. Cytokine function of heat shock proteins. Am J Physiol Cell Physiol 286: C739-744, 2004.
299. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, and Chambers AF. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79: 502-508, 1998.
300. Ueda M, Hung YC, Terai Y, Kanda K, Kanemura M, Futakuchi H, Yamaguchi H, Akise D, Yasuda M, and Ueki M. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin Cancer Res 11: 3225-3232, 2005.
301. Ueda M, Terai Y, Yamashita Y, Kumagai K, Ueki K, Yamaguchi H, Akise D, Hung YC, and Ueki M. Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas. Int J Cancer 98: 335-343, 2002.
302. Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, and Machinami R. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 79: 2336-2344, 1997.
303. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Yoshimastu T, Morita M, and Yasumoto K. Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 49: 55-62, 2005.
304. Urano N, Fujiwara Y, Doki Y, Tsujie M, Yamamoto H, Miyata H, Takiguchi S, Yasuda T, Yano M, and Monden M. Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer 9: 44-49, 2006.
305. Valente G, Mamo C, Bena A, Prudente E, Cavaliere C, Kerim S, Nicotra G, Comino A, Palestro G, Isidoro C, and Beatrice F. Prognostic significance of microvessel density and vascular endothelial growth factor expression in sinonasal carcinomas. Hum Pathol 37: 391-400, 2006.
306. Vande Velde C, Cizeau J, Dubik D, Alimonti J, Brown T, Israels S, Hakem R, and Greenberg AH. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 20: 5454-5468, 2000.
307. Vargas-Roig LM, Gago FE, Tello O, Aznar JC, and Ciocca DR. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 79: 468-475, 1998.
308. Vleugel MM, Greijer AE, Bos R, van der Wall E, and van Diest PJ. c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol 37: 668-674, 2006.
309. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, and van der Wall E. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 58: 172-177, 2005.
310. Wang GL, Jiang BH, Rue EA, and Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
311. Wang Q, He Z, Zhang J, Wang Y, Wang T, Tong S, Wang L, Wang S, and Chen Y. Overexpression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance. Cancer Detect Prev 29: 544-551, 2005.
312. Wang XP, Qiu FR, Liu GZ, and Chen RF. Correlation between clinicopathology and expression of heat shock protein 70 and glucose-regulated protein 94 in human colonic adenocarcinoma. World J Gastroenterol 11: 1056-1059, 2005.
313. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552: 61-85, 2001.
314. Weidner N, Semple JP, Welch WR, and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
315. Wellmann S, Guschmann M, Griethe W, Eckert C, von Stackelberg A, Lottaz C, Moderegger E, Einsiedel HG, Eckardt KU, Henze G, and Seeger K. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 18: 926-933, 2004.
316. White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J, and Murray JC. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 62: 1669-1675, 2002.
317. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, Wood SM, Gatter KC, Harris AL, Pugh CW, Ratcliffe PJ, and Maxwell PH. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 92: 2260-2268, 1998.
318. Winter SC, Shah KA, Campo L, Turley H, Leek R, Corbridge RJ, Cox GJ, and Harris AL. Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma. Clin Cancer Res 11: 7614-7620, 2005.
319. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, and Harris AL. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083, 2000.
320. Xing X, Lai M, Wang Y, Xu E, and Huang Q. Overexpression of glucose-regulated protein 78 in colon cancer. Clin Chim Acta 364: 308-315, 2006.
321. Yamagata M, Hasuda K, Stamato T, and Tannock IF. The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br J Cancer 77: 1726-1731, 1998.
322. Yildiz E, Gokce G, Kilicarslan H, Ayan S, Goze OF, and Gultekin EY. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int 93: 1087-1093, 2004.
323. Yokoyama Y, Sagara M, Sato S, and Saito Y. Value of glutathione S-transferase pi and the oncogene products c-Jun, c-Fos, c-H-Ras, and c-Myc as a prognostic indicator in endometrial carcinomas. Gynecol Oncol 68: 280-287, 1998.
324. Yokoyama Y, Sato S, Futagami M, Fukushi Y, Sakamoto T, Umemoto M, and Saito Y. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol 77: 413-418, 2000.
325. Yoshimura H, Dhar DK, Kohno H, Kubota H, Fujii T, Ueda S, Kinugasa S, Tachibana M, and Nagasue N. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 10: 8554-8560, 2004.
326. Yuan A, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT, and Yang PC. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 89: 475-483, 2000.
327. Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, Yang PC, and Lee YC. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19: 432-441, 2001.
328. Yuan A, Yu CJ, Shun CT, Luh KT, Kuo SH, Lee YC, and Yang PC. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 115: 545-555, 2005.
329. Yudoh K, Kanamori M, Ohmori K, Yasuda T, Aoki M, and Kimura T. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 84: 1610-1615, 2001.
330. Zhang J, Peng B, and Chen X. Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res 11: 7334-7343, 2005.
331. Zhang PL, Pellitteri PK, Law A, Gilroy PA, Wood GC, Kennedy TL, Blasick TM, Lun M, Schuerch C, 3rd, and Brown RE. Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod Pathol 18: 924-932, 2005.
332. Zhang X, Kon T, Wang H, Li F, Huang Q, Rabbani ZN, Kirkpatrick JP, Vujaskovic Z, Dewhirst MW, and Li CY. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res 64: 8139-8142, 2004.
333. Zheng Y, Vig M, Lyons J, Van Parijs L, and Beg AA. Combined deficiency of p50 and cRel in CD4+ T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function. J Exp Med 197: 861-874, 2003.
334. Zhou J, Schmid T, and Brune B. Tumor necrosis factor-alpha causes accumulation of a ubiquitinated form of hypoxia inducible factor-1alpha through a nuclear factor-kappaB-dependent pathway. Mol Biol Cell 14: 2216-2225, 2003.
335. Zhou J, Schmid T, Frank R, and Brune B. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J Biol Chem 279: 13506-13513, 2004.